News | June 10, 2026
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Subscribe To Our Newsletter & Stay Updated
